Abstract

<div>Abstract<p><b>Purpose:</b> This dose-finding phase I study investigated the maximum-tolerated dose (MTD) and safety of weekly nanoparticle albumin-bound rapamycin (<i>nab</i>-rapamycin) in patients with untreatable advanced nonhematologic malignancies.</p><p><b>Experimental Design:</b><i>nab</i>-Rapamycin was administered weekly for 3 weeks followed by 1 week of rest, with a starting dose of 45 mg/m<sup>2</sup>. Additional doses were 56.25, 100, 150, and 125 mg/m<sup>2</sup>.</p><p><b>Results:</b> Of 27 enrolled patients, 26 were treated. Two dose-limiting toxicities (DLT) occurred at 150 mg/m<sup>2</sup> [grade 3 aspartate aminotransferase (AST) elevation and grade 4 thrombocytopenia], and two DLTs occurred at 125 mg/m<sup>2</sup> (grade 3 suicidal ideation and grade 3 hypophosphatemia). Thus, the MTD was declared at 100 mg/m<sup>2</sup>. Most treatment-related adverse events (TRAE) were grade 1/2, including thrombocytopenia (58%), hypokalemia (23%), mucositis (38%), fatigue (27%), rash (23%), diarrhea (23%), nausea (19%), anemia (19%), hypophosphatemia (19%), neutropenia (15%), and hypertriglyceridemia (15%). Only one grade 3 nonhematologic TRAE (dyspnea) and one grade 3 hematologic event (anemia) occurred at the MTD. One patient with kidney cancer had a partial response and 2 patients remained on study for 365 days (patient with mesothelioma) and 238 days (patient with neuroendocrine tumor). The peak concentration (<i>C</i><sub>max</sub>) and area under the concentration–time curve (AUC) of rapamycin increased with dose between 45 and 150 mg/m<sup>2</sup>, except for a relatively low AUC at 125 mg/m<sup>2</sup>. <i>nab</i>-Rapamycin significantly inhibited mTOR targets S6K and 4EBP1.</p><p><b>Conclusions:</b> The clinical dose of single-agent <i>nab</i>-rapamycin was established at 100 mg/m<sup>2</sup> weekly (3 of 4 weeks) given intravenously, which was well tolerated with preliminary evidence of response and stable disease, and produced a fairly dose-proportional pharmacokinetic profile in patients with unresectable advanced nonhematologic malignancies. <i>Clin Cancer Res; 19(19); 5474–84. ©2013 AACR</i>.</p></div>

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.